Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)
We invite you to learn more about:
- Treatment options for aggressive subtypes of non-Hodgkin lymphoma (NHL)
- CAR T-cell therapy for aggressive lymphomas
- Side-effect management
- Questions to ask your healthcare team about treatment options and quality of life issues
Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas at MD Anderson Cancer Center
Houston, TX
Program Support
Support for this program is provided by Bristol Myers Squibb, Eli Lilly and Company, Genmab US & AbbVie Inc., Incyte Corporation, Kite, A Gilead Company, Merck & Company, and MorphoSys US.
Resilience Through Progress: Slow Growing Non-Hodgkin Lymphoma (NHL)
We invite you to learn more about:
- How your NHL subtype determines treatment goals and strategies
- Navigating the uncertainty of a chronic disease
- New therapies on the horizon
- Methods to manage side effects
J.C. Villasboas B., MD
Assistant Professor, Medicine and Oncology
Mayo Clinic College of Medicine and Science
Consultant, Division of Hematology
Director, Mayo Clinic Immune Monitoring
Core Laboratory
Mayo Clinic
Rochester, MN
Program Support
Support for this program provided by Genentech, Inc. & Biogen and Kite, a Gilead Company.